According to Reuter's sources, Sun Pharmaceutical Industries will begin phasing out sales of generic drugs branded as Ranbaxy Laboratories in the United States, following Sun's $3.2 billion acquisition of Ranbaxy in early April.
The rebranding of Ranbaxy drugs sold in the United States is part of an overall strategy to turn around the company that has been hit hard with quality and GMP-related issues. The Ranbaxy brand name is likely to continue to be present in markets outside of the U.S., Reuters sources said.
Sun's Ranbaxy revival plan also includes making Ranbaxy's India plants FDA quality-compliant, lobbying the U.S. FDA to lift bans on imports from Ranbaxy's plants and management restructuring to boost oversight of Indian plants.
Read the Reuters article